Marketing-authorisation holder
Glaxosmithkline Inc
305 medicines in 1 country, as authorisation holder and manufacturer.
Loading your page…
Loading your page…
Marketing-authorisation holder
305 medicines in 1 country, as authorisation holder and manufacturer.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
1–25 of 305
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ADVAIR250 mcg / act + 25 mcg / act · Aerosol (Metered-Dose) | Fluticasone, Salmeterol | Canada | Marketed | 2001 |
| ADVAIR125 mcg / act + 25 mcg / act · Aerosol (Metered-Dose) | Fluticasone, Salmeterol | Canada | Marketed | 2001 |
| ADVAIR 100 DISKUS100 mcg / act + 50 mcg / act · Powder | Fluticasone, Salmeterol | Canada | Marketed | 1999 |
| ADVAIR 250 DISKUS250 mcg / act + 50 mcg / act · Powder | Fluticasone, Salmeterol | Canada | Marketed | 1999 |
| ADVAIR 500 DISKUS500 mcg / act + 50 mcg / act · Powder | Fluticasone, Salmeterol | Canada | Marketed | 1999 |
| ANORO ELLIPTA62.5 mcg / act + 25 mcg / act · Powder | Umeclidinium bromide, Vilanterol | Canada | Marketed | 2014 |
| AREXVY120 mcg / 0.5 ml · Powder For Suspension | Respiratory syncytial virus vaccines | Canada | Marketed | 2023 |
| ARNUITY ELLIPTA200 mcg / act · Powder | Fluticasone | Canada | Marketed | 2015 |
| ARNUITY ELLIPTA100 mcg / act · Powder | Fluticasone | Canada | Marketed | 2016 |
| AVAMYS27.5 mcg / act · Spray (Metered-Dose) | Fluticasone | Canada | Marketed | 2007 |
| AVODART0.5 mg · Capsule | Dutasteride | Canada | Marketed | 2003 |
| BENLYSTA120 mg / vial · Powder For Solution | Belimumab | Canada | Marketed | 2011 |
| BENLYSTA400 mg / vial · Powder For Solution | Belimumab | Canada | Marketed | 2011 |
| BENLYSTA200 mg / 1 ml · Solution | Belimumab | Canada | Marketed | 2018 |
| BEXSERO25 mcg / 0.5 ml + 50 mcg / 0.5 ml + 50 mcg / 0.5 ml + 50 mcg / 0.5 ml · Suspension | Outer membrane vesicles, Recombinant neisseria meningitidis group b fhbp fusion protein, Recombinant neisseria meningitidis group b nada protein, Recombinant neisseria meningitidis group b nhba fusion protein | Canada | Marketed | 2014 |
| BLENREP70 mg / vial · Powder For Solution | Belantamab mafodotin | Canada | Marketed | 2025 |
| BLENREP100 mg / vial · Powder For Solution | Belantamab mafodotin | Canada | Marketed | 2025 |
| BOOSTRIX2 unit / 0.5 ml + 8 mcg / 0.5 ml + 2.5 mcg / 0.5 ml + 8 mcg / 0.5 ml + 20 unit / 0.5 ml · Suspension | Diphtheria toxoid, Filamentous haemagglutinin, Pertactin, Pertussis toxoid, Tetanus toxoid | Canada | Marketed | 2007 |
| BOOSTRIX-POLIO2.5 lf / 0.5 ml + 8 mcg / 0.5 ml + 40 d / 0.5 ml + 8 d / 0.5 ml + 32 d / 0.5 ml + 2.5 mcg / 0.5 ml + 8 mcg / 0.5 ml + 5.0 lf / 0.5 ml · Suspension | Diphtheria toxoid adsorbed, Filamentous haemagglutinin adsorbed, Inactivated poliovirus type i, Pertactin adsorbed, Pertussis toxoid adsorbed, Tetanus toxoid | Canada | Marketed | 2010 |
| BREO ELLIPTA100 mcg / act + 25 mcg / act · Powder | Fluticasone, Vilanterol | Canada | Marketed | 2013 |
| BREO ELLIPTA200 mcg / act + 25 mcg / act · Powder | Fluticasone, Vilanterol | Canada | Marketed | 2015 |
| CERVARIX20 mcg / 0.5 ml + 20 mcg / 0.5 ml · Suspension | Recombinant human papillomavirus type l1 protein | Canada | Marketed | 2010 |
| CLAVULIN 125 F ORAL SUS125 mg / 5 ml + 31.25 mg / 5 ml · Powder For Suspension | Amoxicillin, Clavulanic acid | Canada | Marketed | 1992 |
| CLAVULIN 200200 mg / 5 ml + 28.5 mg / 5 ml · Powder For Suspension | Amoxicillin, Clavulanic acid | Canada | Marketed | 1998 |
| CLAVULIN 250 F ORAL SUS250 mg / 5 ml + 62.5 mg / 5 ml · Powder For Suspension | Amoxicillin, Clavulanic acid | Canada | Marketed | 1992 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Canada | 305 | 93 | 212 | CompaniesAll medicines |
Also in the registers of Brazil
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Anvisa, official medicine/API manufacturer factual export, HTTP source version Fri, 09 Oct 2026 08:21:54 GMT, acquired 2026-10-09; exact unmodified native identifiers and fields preserved.
Licence: Brazil federal factual open-data reuse; Decreto 8777/2016 consolidated article 4 and third-party exceptions
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Report an error or request removalCorrections from the company itself are welcome.
Other companies in the same group.